Stanford Investment Group’s iShares Biotechnology ETF IBB Stock Holding History

Stanford Investment Group’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-570	Closed	-$50K	–	361
2016 Q1	$50K	Hold	570	–	–	0.03%	138
2015 Q4	$64K	Hold	570	–	–	0.03%	110
2015 Q3	$58K	Hold	570	–	–	0.04%	113
2015 Q2	$70K	Hold	570	–	–	0.05%	113
2015 Q1	$65K	Buy	+570	New	+$62.9K	0.05%	115

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

Societe Generale $14.1B AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Stanford Investment Group's IBB Position: Q2 2016 in Review

Stanford Investment Group sold out of iShares Biotechnology ETF (IBB) in Q2 2016, closing a stake of 570 shares — an estimated $50K sold.

Stanford Investment Group first reported a position in IBB in Q1 2015 and held it in 5 quarters. The position peaked at $70K in Q2 2015. 429 funds tracked by Wall St. Rank hold IBB as of Q2 2016.

Stanford Investment Group reported no remaining iShares Biotechnology ETF position as of Q2 2016 after selling out during the quarter.
Stanford Investment Group sold 570 iShares Biotechnology ETF shares in Q2 2016, an estimated $50K.
Stanford Investment Group first reported a position in iShares Biotechnology ETF in Q1 2015 and held it in 5 quarters.
Stanford Investment Group's iShares Biotechnology ETF position peaked at $70K in Q2 2015.
429 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2016.

Based on Stanford Investment Group's 13F filing for Q2 2016, filed 10 Nov 2016.